ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ARNA Stock Price » ARNA Stock News

Arena Share News

 Arena Pharmaceuticals (mm) Stock Price
ARNA Stock Price
 Arena Pharmaceuticals (mm) Stock Chart
ARNA Stock Chart
 Arena Pharmaceuticals (mm) Stock News
ARNA Stock News
 Arena Pharmaceuticals (mm) Company Information
ARNA Company Information
 Arena Pharmaceuticals (mm) Stock Trades
ARNA Stock Trades

Arena: FDA Accepts Resubmitted Application For Weight-Loss Drug Lorcaserin

DOW JONES NEWSWIRES Arena Pharmaceuticals Inc. (ARNA) and its partner, Eisai Co.'s (ESALY, 4523.TO) U.S. unit, said the U.S. Food and Drug Administration accepted their resubmitted new drug application for antiobesity drug lorcaserin. Shares of Arena jumped 11% premarket to $1.78 as the biotechnology company said the FDA assigned a new Prescription Drug User Fee Act target date of June 27. The stock has gained 15% over the past three months through Monday's close. The FDA requested in 2010 multiple sets of new data from Arena about lorcaserin, and the company said last week it submitted a response to the agency's two remaining concerns: the link between mammary tumors and a particular hormone in rats and deeper understanding about the drug's activity at three serotonin receptor subtypes. Arena is one of three small drug developers that had its respective weight-loss pill candidates rejected by the FDA recently. Vivus Inc. (VVUS) and Orexigen Therapuetics Inc. (OREX) were also turned down by the agency, which raised major safety concerns about all three treatments. Vivus resubmitted its application in October, while Orexigen suspended development of its weight-loss drug Contrave. Eisai's American depositary shares closed Monday at $40.76 and were inactive premarket. -By Melodie Warner, Dow Jones Newswires; 212-416-2283;

Stock News for Arena (ARNA)
11/24/201508:00:00Arena Pharmaceuticals to Present at Piper Jaffray 27th Annual...
11/19/201508:00:00Arena Pharmaceuticals to Host Analyst & Investor Day on December...
11/12/201511:00:033 Dangerous Stocks
11/10/201516:20:28Current Report Filing (8-k)
11/10/201516:00:00Arena Pharmaceuticals Reports Third Quarter 2015 Financial Results...
11/09/201516:53:33Quarterly Report (10-q)
11/06/201512:20:29Why Orexigen Therapeutics, Inc.'s Stock Is Losing Weight Today
11/04/201508:00:00Arena Pharmaceuticals to Host Third Quarter 2015 Financial Results...
11/02/201508:00:00Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin...
11/02/201507:04:023 Things You Never Knew About Medicare
10/30/201512:25:20Here's Why Arena Pharmaceuticals, Inc. Is Struggling Today
10/29/201516:36:00Current Report Filing (8-k)
10/29/201508:00:00Arena Pharmaceuticals Initiates a Phase 1b Clinical Trial of...
10/27/201516:14:37Current Report Filing (8-k)
10/27/201516:00:00Arena Pharmaceuticals Announces New Strategic Focus and Cost...
10/27/201508:00:00Arena Pharmaceuticals Issued Additional Patent Covering BELVIQ®...
10/26/201506:24:42Vivus: Qsymia Takes Second Place This Week- Is It A Sign?
10/26/201506:18:58Orexigen: Contrave Sales Flat- Big Bump In Market Share
10/26/201506:15:38Arena: Belviq Sales Drop To Third Place- Can A Turnaround Happen?
10/19/201515:44:00IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation...

Arena Pharmaceuticals and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations